Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 9 | 2023 | 158 | 2.300 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 2 | 2019 | 7 | 0.780 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2022 | 176 | 0.700 |
Why?
|
| HLA-DRB1 Chains | 2 | 2022 | 17 | 0.670 |
Why?
|
| Amino Acids | 1 | 2018 | 16 | 0.620 |
Why?
|
| Rheumatoid Factor | 1 | 2018 | 16 | 0.620 |
Why?
|
| African Americans | 1 | 2018 | 47 | 0.610 |
Why?
|
| Cotinine | 1 | 2016 | 7 | 0.530 |
Why?
|
| Smoking | 1 | 2016 | 100 | 0.500 |
Why?
|
| Rheumatic Diseases | 3 | 2020 | 17 | 0.410 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2022 | 198 | 0.390 |
Why?
|
| Antirheumatic Agents | 4 | 2019 | 35 | 0.370 |
Why?
|
| Aged | 6 | 2021 | 1740 | 0.320 |
Why?
|
| Methotrexate | 2 | 2018 | 17 | 0.300 |
Why?
|
| Glucocorticoids | 2 | 2018 | 20 | 0.290 |
Why?
|
| Male | 9 | 2021 | 6754 | 0.280 |
Why?
|
| Middle Aged | 7 | 2021 | 3601 | 0.270 |
Why?
|
| Female | 10 | 2021 | 9103 | 0.260 |
Why?
|
| Genotype | 3 | 2018 | 442 | 0.260 |
Why?
|
| Humans | 13 | 2023 | 14537 | 0.240 |
Why?
|
| Adult | 7 | 2021 | 5913 | 0.220 |
Why?
|
| Autoantibodies | 1 | 2023 | 49 | 0.200 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2014 | 7 | 0.200 |
Why?
|
| HLA Antigens | 1 | 2022 | 50 | 0.200 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 106 | 0.190 |
Why?
|
| Rheumatology | 1 | 2020 | 18 | 0.170 |
Why?
|
| Sulfasalazine | 1 | 2018 | 4 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2018 | 5 | 0.150 |
Why?
|
| Alleles | 1 | 2018 | 143 | 0.150 |
Why?
|
| Haplotypes | 1 | 2018 | 125 | 0.150 |
Why?
|
| Biological Products | 1 | 2017 | 7 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 43 | 0.150 |
Why?
|
| South Africa | 5 | 2022 | 7596 | 0.140 |
Why?
|
| Global Health | 1 | 2018 | 193 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2018 | 480 | 0.140 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 7 | 0.130 |
Why?
|
| Tobacco, Smokeless | 1 | 2016 | 7 | 0.130 |
Why?
|
| Health Surveys | 1 | 2016 | 59 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 280 | 0.120 |
Why?
|
| Registries | 3 | 2021 | 91 | 0.120 |
Why?
|
| Biomarkers | 1 | 2016 | 327 | 0.120 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2014 | 4 | 0.120 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2014 | 4 | 0.120 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2014 | 4 | 0.120 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2014 | 8 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 20 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 14 | 0.120 |
Why?
|
| Genetics, Population | 1 | 2013 | 52 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2019 | 889 | 0.090 |
Why?
|
| Sex Factors | 2 | 2021 | 227 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 99 | 0.080 |
Why?
|
| Linear Models | 2 | 2018 | 83 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 370 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 279 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 563 | 0.060 |
Why?
|
| Risk Factors | 2 | 2023 | 1475 | 0.050 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2023 | 2 | 0.050 |
Why?
|
| Peptides, Cyclic | 1 | 2023 | 8 | 0.050 |
Why?
|
| Lim Kinases | 1 | 2022 | 4 | 0.050 |
Why?
|
| Ear, External | 1 | 2021 | 1 | 0.050 |
Why?
|
| Deafness | 1 | 2021 | 3 | 0.050 |
Why?
|
| Hip Dislocation, Congenital | 1 | 2021 | 4 | 0.050 |
Why?
|
| Age of Onset | 1 | 2021 | 32 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 39 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 231 | 0.050 |
Why?
|
| Growth Disorders | 1 | 2021 | 56 | 0.050 |
Why?
|
| Age Factors | 1 | 2021 | 370 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2019 | 22 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 149 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 199 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 253 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 296 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 1 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 125 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 20 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 38 | 0.030 |
Why?
|